Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Sold by Jane Street Group LLC

Jane Street Group LLC trimmed its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 58.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,003 shares of the company’s stock after selling 33,902 shares during the period. Jane Street Group LLC’s holdings in Design Therapeutics were worth $129,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. boosted its stake in shares of Design Therapeutics by 61.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,740 shares of the company’s stock valued at $8,612,000 after buying an additional 609,939 shares during the period. Baker BROS. Advisors LP increased its position in Design Therapeutics by 2.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,743,725 shares of the company’s stock worth $9,381,000 after buying an additional 48,431 shares during the period. Paloma Partners Management Co bought a new position in Design Therapeutics during the third quarter worth $64,000. PDT Partners LLC raised its position in shares of Design Therapeutics by 33.1% during the third quarter. PDT Partners LLC now owns 36,099 shares of the company’s stock valued at $194,000 after buying an additional 8,972 shares during the last quarter. Finally, Walleye Capital LLC raised its holdings in Design Therapeutics by 16.3% in the 3rd quarter. Walleye Capital LLC now owns 70,000 shares of the company’s stock valued at $377,000 after acquiring an additional 9,788 shares in the last quarter. 56.64% of the stock is currently owned by hedge funds and other institutional investors.

Design Therapeutics Price Performance

Shares of DSGN stock opened at $4.11 on Tuesday. The stock has a fifty day moving average price of $6.03 and a 200 day moving average price of $5.25. The stock has a market cap of $232.71 million, a P/E ratio of -4.84 and a beta of 1.86. Design Therapeutics, Inc. has a one year low of $2.24 and a one year high of $7.77.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.